Shilanski & Associates’s Novo Nordisk NVO Stock Holding History

Shilanski & Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,908	Closed	-$584K	–	112
2024 Q3	$584K	Sell	4,908 -230	-4%	-$30.7K	0.19%	61
2024 Q2	$733K	Sell	5,138 -279	-5%	-$37K	0.25%	63
2024 Q1	$698K	Buy	5,417 +320	+6%	+$38.1K	0.24%	63
2023 Q4	$527K	Sell	5,097 -228	-4%	-$22.5K	0.2%	64
2023 Q3	$484K	Sell	5,325 -155	-3%	-$13.7K	0.2%	68
2023 Q2	$443K	Buy	5,480 +28	+0.5%	+$2.29K	0.18%	73
2023 Q1	$430K	Sell	5,452 -6	-0.1%	-$425	0.19%	71
2022 Q4	$369K	Buy	+5,458	New	+$320K	0.16%	74
2022 Q3	–	Sell	-5,204	Closed	-$290K	–	193
2022 Q2	$290K	Buy	5,204 +64	+1%	+$3.55K	0.14%	81
2022 Q1	$287K	Buy	5,140 +662	+15%	+$34K	0.12%	92
2021 Q4	$251K	Buy	+4,478	New	+$243K	0.11%	96

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Shilanski & Associates's NVO Position: Q4 2024 in Review

Shilanski & Associates sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 4,908 shares — an estimated $584K sold.

Shilanski & Associates first reported a position in NVO in Q4 2021 and held it in 11 quarters. The position peaked at $733K in Q2 2024. 1,665 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

Shilanski & Associates reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
Shilanski & Associates sold 4,908 Novo Nordisk shares in Q4 2024, an estimated $584K.
Shilanski & Associates first reported a position in Novo Nordisk in Q4 2021 and held it in 11 quarters.
Shilanski & Associates's Novo Nordisk position peaked at $733K in Q2 2024.
1,665 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Shilanski & Associates's 13F filing for Q4 2024, filed 21 Jan 2025.